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Abstract It has recently been shown that the oxygen-
regulated factors erythropoietin (Epo) and vascular endo-
thelial growth factor (VEGF) confer protection on different
cells, including neuronal-derived ones. The receptors for
Epo and VEGF are widely expressed in different organs.
Since mammalian auditory hair cells can irreversibly be
damaged by different agents, we aimed to identify oto-
protective compounds. We focused on the role of Epo and
VEGF in the inner ear and review the recent studies. Epo
and its receptor are expressed in the inner ear. In vitro
experiments on auditory hair cells showed a protective
effect of Epo in ischemia- and gentamicin-induced hair cell
damage. In contrast, an in vivo study using an animal
model of noise-induced hearing loss showed a negative
effect of Epo. Also VEGF and its receptors are expressed in
the inner ear. Changes in the expression of VEGF or its
receptors have been found in the cochlea after noise
exposure, transcranial vibration and diabetic or aged ani-
mals. Until now, there are no studies about a direct effect of
VEGF on auditory hair cells in vitro or in vivo. We could
exclude a protective effect of VEGF on gentamicin-
induced auditory hair cell damage in vitro. Thus, we con-
clude that Epo but not VEGF has a protective effect on
auditory hair cell damage at least in vitro. (Part of a multi-
author review.)
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Introduction
Hearing loss is one of the most relevant chronic diseases in
aging. It is estimated that close to 250 million people
worldwide suffer from some form of hearing impairment,
and 1 of every 1,000 children is deaf by the age of 3. The
auditory (cochlear) region in the inner ear is responsible for
the sense of hearing. In the organ of Corti, which is located
inside the cochlea, the mechano-electrical transduction of
sound takes place. The organ of Corti is composed of a
single layer of approximately 3,500 inner hair cells and
three rows of outer hair cells, as well as a number of dif-
ferent types of supporting cells. Hair cells are the most
vulnerable elements in the cochlea. Their death commonly
occurs following acoustic trauma or exposure to ototoxins,
such as aminoglycoside antibiotics and cisplatin. Since
these hair cells do not regenerate, their damage leads to a
lifelong hearing impairment and thus represents the most
common cause of permanent hearing loss.
It appears that hair cell death occurs via an apoptotic
process [1]. The mechanisms of sensory hair cell degen-
eration in response to different ototoxic stimuli share a final
common pathway: the caspase activation [2]. Currently, the
only effective clinical intervention is prevention from
exposure to known ototoxic insults. Potential causally
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based therapies have yet to emerge. At present, there is
great interest in finding otoprotective compounds.
Oxygen homeostasis in mammals is controlled through
respiratory and cardiac responses. The key factors in
hypoxia-induced pathways are the hypoxia-induced factors
(HIFs). An extensive review on oxygen sensing and HIFs by
Webb et al. can be found in this issue. In short, under
hypoxic conditions, prolyl-hydroxylase domain and factor-
inhibiting HIF1 hydroxylases are inactive. The alpha sub-
unit of HIF is stable under hypoxia and translocates into the
cell nucleus where it binds to the HIF beta subunit, which is
oxygen independent. HIF then binds to target genes through
a recognition DNA sequence (hypoxic response ele-
ments, HRE). Interaction with the co-activator CBP/p300
induces or represses a large number of genes. These are
genes of erythropoiesis and iron metabolism [erythropoietin
(Epo), transferrin, transferrin-receptor, etc.], genes of vas-
cular regulation [vascular endothelial growth factor
(VEGF) and its receptor 1, i-NOS, heme oxygenase 1, etc.],
genes of glucose uptake and glycolysis (glucose transporter-
1, GAPDH, etc.) and genes of apoptosis (BNIP3). At least
100 HIF-dependent genes have been recognized [3–5].
In the last years it has been shown that oxygen-regulated
factors such as Epo and VEGF confer protection on dif-
ferent cells, including neuronal-derived ones. Their
neuroprotective effects involve suppression of cell death
pathways mediated by activation of antiapoptotic proteins
through the transcription factor NFjB and inhibiting
proapoptotic signaling by BAD, caspases and other effec-
tors [6, 7]. Here we will review the role of Epo and VEGF
as a possible protective factor in the inner ear.
Erythropoietin
Erythropoietin and neuroprotection
Epo is a glycoprotein hormone that is manly produced in
the fetal liver and adult kidney and promotes survival,
proliferation and differentiation of erythroid progenitor
cells. Binding of Epo to the Epo receptor represses apop-
tosis and allows the final maturation of erythroid progenitor
cells to erythrocytes [8]. New studies found that many
other organs, including the central nervous system [9] and
the retina [10], also express Epo and its receptor. In the
central nervous system, Epo has neuroprotective, neuro-
trophic and anti-inflammatory properties, and it influences
the neurogenesis, angiogenesis and the vascular perme-
ability induced by VEGF [11]. In vivo, Epo has been tested
as a potential therapeutic cytokine in several animal models
including stroke, multiple sclerosis, schizophrenia, Par-
kinson’s disease, epilepsy, brain trauma and spinal cord
injury [11]. In clinical studies, Epo has improved patients’
functional outcome in the Go¨ttingen-Epo-Stroke study
[12]. A multicenter phase II/III trial is being conducted [13,
14]. A phase II trial demonstrated an improvement of
schizophrenia-related cognitive performance of chronic
schizophrenic patients by Epo add-on medicamentation
[15]. Also in retinopathies, such as models of glaucoma
[16, 17], age-related macular degeneration and retinitis
pigmentosa [10], Epo has protective effects.
Erythropoietin in the cochlea
Recently, the effect of Epo in the inner ear was tested in
different studies. Caye´-Thomasen et al. [18] found for the
first time expression of Epo and its receptor in the inner
ear. Epo expression was exclusively found in the support-
ing cells of the organ of Corti. In the rest of the cochlea,
spiral ligament fibrocytes, some cells of the stria vascularis
and endothelial cells expressed Epo receptor in guinea pig.
Our study showed expression of Epo receptor also in
auditory hair cells and supporting cells of the organ of
Corti in newborn and adults rats [19].
A direct effect of Epo in vitro on auditory hair cells was
tested by two different studies using explant cultures of the
rat organ of Corti. The first study showed a protective
effect of Epo in ischemia-induced damage [20], while in
the second study we demonstrated a dose-dependent pro-
tective effect against gentamicin-induced hair cell damage
[19]. However, in both studies only a partial effect was
observed compared to untreated control explants. A toxic
effect of Epo itself was excluded.
The first in vivo study using an animal model of noise-
induced hearing loss showed a negative effect of Epo [21].
In the first trial guinea pigs were treated with Epo to the
round window membrane 24 h after noise exposure either
by pump for a week or by single dose in the middle ear. No
improvement of hearing occurred in any group. In the
second trial rats had a single dose Epo 1 or 14 h after noise
exposure. After 8 days in both groups, the hearing had
partly recovered, whereas the hearing loss of Epo-treated
animals was significantly worse than in controls. In the third
trial, rats were injected with Epo intraperitoneally 1 h
before noise exposure. The hearing of the Epo-treated ani-
mals was significantly worse than controls [21]. The authors
of that study suggest that Epo mediates a vasoconstrictive
effect in part through the same pathways activating vaso-
constriction during noise exposure. This may lead to a
synergistic reduction of cochlear blood flow and an increase
of the hearing loss when treating rats with Epo and exposing
them to noise as rats are known to be more sensitive to a
decrease in blood flow during noise exposure [21, 22].
Finally, a study with end-stage renal failure patients had a
significant improvement of hearing after treatment with Epo
120 U/kg per week for 5–8 months. However, this effect
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could be due to the improvement of anemia or due to a
direct effect of Epo in the inner ear itself [23].
VEGF
VEGF and neuroprotection
VEGF was first discovered as the vascular permeability
factor [24]. Shortly thereafter, VEGF was also isolated as
an angiogenic factor that stimulates endothelial cells to
proliferate, migrate and survive in a serum-poor environ-
ment [25]. In addition to a cellular role for VEGF in
regulating proliferation, migration, permeability and acting
as an antiapoptotic molecule, recently neuroprotective
properties were found. In vitro, VEGF has a direct effect on
cultured motor neurons protecting them from toxicity due
to hypoxia, increased reactive oxygen species, serum
deprivation and glutamate-induced exocitotoxicity [26]. In
vivo, VEGF is expressed in the spinal cord neurons and
astrocytes, which signal trough VEGFR-2 and neuropilin-1
located on motor neurons and peripheral nerve axons [26].
Recent work revealed a role for reduced VEGF expression
in the pathogenesis of amyotrophic lateral sclerosis [27].
VEGF also has an important role in visual function [28].
VEGF in the cochlea
VEGF and VEGF-1 and VEGF-2 receptors have been
found in different cell types in the cochlea, for example, in
the organ of Corti in Deiters cells, pillar cells, inner and
outer hair cells [29–31]. A recent study comparing the
alterations of VEGF and the VEGF-receptors after noise
exposure postulated that modulation of VEGF and its
receptors may be part of a neuroprotective mechanism in
response to noise [31]. Other studies showed reduced
VEGF-expression in the cochlea and in the stria vascularis
of aged animals [32], VEGF and VEGF-R2 expression was
induced in the cochlea by transcranial vibration [33], and in
noise-exposed animals an increase in VEGF was found
[34]. Recently, an increased cochlear expression of VEGF,
iNOS and eNOS was detected in the diabetic rat, sug-
gesting that this upregulation may be involved in the
pathogenesis of cochlea functional loss [35]. We tested the
effect of VEGF on gentamicin-induced hair cell loss in
vitro following an earlier protocol [19] (Fig. 1). A direct
toxic effect of VEGF on auditory hair cells could be
excluded. Quantitative analysis of surviving outer hair cells
showed no statistically significant reduction of gentamicin-
induced hair cell loss in organs of Corti treated with VEGF
and gentamicin compared to gentamicin control treatment
only. Thus, we exclude a protective effect of VEGF under
these conditions in vitro.
Conclusions and outlook
Epo and VEGF are hypoxically regulated genes. In the last
years, a direct neuroprotective effect for Epo and VEGF
could be shown [6, 7]. Both factors act by binding to
specific receptors, Epo binds to the Epo-receptor, and
VEGF binds to the VEGF-1 and VEGF-2-receptors. In the
cochlea Epo and its receptor as well as VEGF and its
receptors have been detected. As we showed previously,
significantly less hair cell loss occurred in the organs of
Fig. 1 Effect of VEGF on gentamicin-induced hair cell damage.
Representative photographs of organs of Corti labeled with Texas Red
X-phalloidin are shown. Untreated organs of Corti demonstrate three
orderly rows of outer hair cells and a single row of inner hair cells. To
induce severe hair cell damage, organs of Corti were cultured in cell
culture medium supplemented with gentamicin [19]. Organs of Corti
were pre-treated for 2 h with increasing concentrations of VEGF (50,
100 and 300 ng/ml) [36] and exposed to VEGF and gentamicin for an
additional 24 h. Culture with VEGF in addition to gentamicin did not
decrease hair cell loss compared to gentamicin treatment only. In
contrast to VEGF, Epo showed a dose-dependent protective effect on
gentamicin-induced hair cell damage in vitro [19]
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Corti that were pretreated with 0.1 U/ml Epo as compared
with samples treated with gentamicin only in vitro [19].
Another study proved a protective effect of Epo in ische-
mia-induced damage in vitro [20]. However, an in vivo
study of noise-induced hearing loss showed a negative
effect of Epo. In our results we did not find a significant
reduction of auditory hair cell loss in conditions where the
organs of Corti were co-cultured with VEGF and genta-
micin compared to gentamicin control treatment in vitro.
Of note, we investigated for the first time the effect of
VEGF on gentamicin-damaged hair cells, and our in vitro
data are limited to 6-day-old rats, but they provide evi-
dence that VEGF is not able to protect auditory hair cells
from gentamicin-induced hair cell damage. Up to now, the
role of Epo and VEGF in the inner ear is still unclear.
However, we do not exclude the possibility that Epo and
VEGF protect auditory hair cells from other types of
damage, such as hypoxia, aging or different drugs in vivo.
Thus, future studies are needed to clarify if Epo and VEGF
have otoprotective effects.
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